Teva Pharmaceutical Industries Limited (TEVA) 8-K Regulation FD Disclosure

Exhibit 99.1

Selected financial data by segment (unaudited)

	North America Segment
	Year ended December 31,						Three months ended
	2017			2016			December 31,			September 30,			June 30,			March 31,
							2017
	(Unaudited, U.S.$ in millions)
Revenues	$	12,141		$	11,778		$	2,689		$	3,043		$	3,169		$	3,240
Gross profit		7,509			8,567			1,538			1,833			2,058			2,080
R&D expenses		969			1,040			192			230			280			267
S&M expenses		1,475			1,525			317			325			392			441
G&A expenses		533			496			101			149			144			139
Other income		(92	)		(30	)		(10	)		(1	)		(8	)		(73	)
Segment profit*	$	4,624		$	5,536		$	938		$	1,130		$	1,250		$	1,306

	Europe Segment
	Year ended December 31,						Three months ended
	2017			2016			December 31,			September 30,		June 30,			March 31,
							2017
	(Unaudited, U.S.$ in millions)
Revenues	$	5,466		$	4,969		$	1,450		$	1,380	$	1,295		$	1,341
Gross profit		2,910			2,722			763			721		692			734
R&D expenses		390			383			78			101		105			106
S&M expenses		1,153			1,304			289			289		296			279
G&A expenses		354			377			96			90		89			79
Other income		(16	)		(9	)		(1	)		—		(17	)		2
Segment profit*	$	1,029		$	667		$	301		$	241	$	219		$	268

	Growth Markets Segment
	Year ended December 31,						Three months ended
	2017			2016			December 31,			September 30,			June 30,		March 31,
							2017
	(Unaudited, U.S.$ in millions)
Revenues	$	3,395		$	4,015		$	910		$	882		$	885	$	718
Gross profit		1,433			1,816			390			351			400		292
R&D expenses		154			205			25			35			47		47
S&M expenses		672			759			169			158			187		158
G&A expenses		189			225			45			51			45		48
Other income		(8	)		(10	)		(4	)		(3	)		—		(1	)
Segment profit*	$	426		$	637		$	155		$	110		$	121	$	40

* Segment profit is comprised of gross profit for the segment, less research and development, selling and marketing and general and administrative expenses and other income related to each segment. Segment profit does not include amortization and certain other items.